Background and Objective Cyclosporine has been observed to precipitate cushingoid features in kidney transplant recipients already on prednisolone. Some pharmacokinetic studies have demonstrated increased prednisolone exposure in patients on cyclosporine therapy compared with azathioprine, whereas other studies have found no difference. The objective of this study was to determine whether cyclosporine impacts on prednisolone exposure as compared with tacrolimus. Methods Adult male kidney transplant recipients treated with prednisolone and either cyclosporine or tacrolimus were recruited for pharmacokinetic blood sampling at the outpatient clinic at the Princess Alexandra Hospital, Brisbane, Australia. Prednisolone plasma concentrations were determined using ultra-high-performance liquid chromatography. Dose-adjusted area under the plasma concentration-time curve (AUC) of free and total prednisolone was estimated using a previously developed limited sampling strategy and non-compartmental analysis.
Introduction
Cyclosporine is known to interact with a range of different drugs with notable examples including statins [1, 2] , digoxin [3, 4] , ezetimibe [5] , caspofungin [6] and aliskiren [7] . The unifying suspected mechanism for these interactions is cyclosporine inhibition of the efflux transporter P-glycoprotein (p-gp) and/or other efflux or influx transporters such as organic anion transporter peptide 1B1 (OATP1B1) [1, 2] . Inhibition of prednisolone apparent clearance (CL/F) by cyclosporine, in the broad sense, was first hypothesized in 1984. This was based on the observation that kidney transplant patients on cyclosporine were more likely to display a cushingoid appearance than patients on azathioprine. The authors tested this hypothesis and indeed found that the CL/F of total prednisolone was significantly higher in 27 kidney transplant recipients on azathioprine compared with 10 recipients on cyclosporine [8] . However, six subsequent studies, also using azathioprine as a comparator, arrived at conflicting conclusions [9] [10] [11] [12] [13] [14] . It therefore remains an open question whether or not cyclosporine inhibits the CL/F of prednisolone in solid organ transplant recipients. Given that prednisolone remains a cornerstone in immunosuppression therapy in solid organ transplantation, it is important to determine whether switching patients from or to cyclosporine affects prednisolone treatment.
We present a prospective pharmacokinetic study specifically designed to compare differences in dose-adjusted exposure to free and total prednisolone in adult male kidney transplant recipients treated with either cyclosporine or tacrolimus.
Methods

Participants
A prospective, observational cohort study was conducted between August 2011 and May 2012. Adult (aged C18 years) male kidney transplant recipients on a daily oral maintenance dose of prednisolone between 5 and 12.5 mg were recruited into the study. To be eligible, subjects were required to have undergone living or deceased donor kidney transplantation at least 12 months prior to enrolment and to be receiving ongoing outpatient follow-up at the Princess Alexandra Hospital, Brisbane, Australia. In addition, subjects had to be clinically stable and receiving concurrent immunosuppressant therapy with either cyclosporine or tacrolimus. Exclusion criteria included (1) a history of alcohol abuse or significant liver disease; (2) glucocorticoid therapy for any other reason apart from the prevention of rejection; and (3) treatment with pulse steroids in the previous 2 months. On the day of blood sampling the patients' medical history was recorded. Prednisolone and calcineurin inhibitor dose changes within the previous 7 days were not allowed. Medications were screened for p-gp and cytochrome P450 3A4 (CYP3A4) inhibitors/inducers. The study protocol adhered to the declaration of Helsinki and was approved by the Princess Alexandra Hospital and University of Queensland Ethics Committees. All participants provided written informed consent.
Drug Analysis
Each subject's prednisolone exposure was measured on a single occasion in the outpatient setting. Prior to arrival at the hospital, subjects were instructed to consume a light, non-fatty breakfast. All blood samples were taken via a peripherally inserted intravenous cannula. Blood samples were collected in EDTA tubes immediately prior to and 1, 2, 4 and 6 h after morning medications were taken. Plasma was prepared within 30 min by 10 min centrifugation at approximately 1,750 g. Plasma was stored at -20°C until analysis. Total and free prednisolone concentrations were determined in plasma using ultra-high-performance liquid chromatography (UHPLC) with tandem mass spectrometric detection [15] . For free prednisolone measurement, plasma ultrafiltrate was prepared by temperature-controlled ultrafiltration. The limit of quantitation for prednisolone was 5 nmol/L and linearity extended to 2,000 nmol/L. The intra-assay CV was \5 % (4.9, 3.9 and 2.3 % for 23, 125 and 533 nmol/L, respectively) and the inter-assay CV was \10 % for all analytes.
Estimation of Exposure
It was decided a priori to estimate prednisolone exposure employing limited sampling strategies (LSS) previously developed in a cohort of kidney transplant recipients at the Princess Alexandra Hospital [16] . Dose-adjusted total prednisolone area under the concentration-time curve (AUC) from 0 to 6 h (d-tAUC 0-6) was estimated using Eq. 1:
where C n is the total prednisolone concentration sampled after 2 and 4 h. Dose-adjusted free prednisolone AUC from 0 to 12 h (dfAUC 0-12 ) was estimated using Eq. 2:
where C n is the free prednisolone concentration sampled after 1, 2 and 4 h. For completeness in a secondary analysis, AUC from 0 to t max (AUC 0-tmax ) and from 0 to infinity (AUC 0-? ), the maximum measured concentration (C max ) and the elimination rate constant (k e ) of total and free prednisolone were also estimated based on non-compartmental analysis using the linear trapezoidal rule (with any extrapolation done assuming first-order pharmacokinetics). All exposure parameters were adjusted for prednisolone dose. All calculations were carried out using STATA 12.1 (StataCorp, College Station, TX, USA).
Statistical Analysis
A pre-study power calculation determined that 53 subjects were sufficient to detect an 8 nmolÁh/L/mg difference in free prednisolone dose-adjusted exposure, with a power of 80 % and an alpha of 5 %. Based on a previous study [16] , the standard deviation (SD) was assumed to be 10 nmolÁh/ L/mg. The descriptive statistics used were medians with 10th and 90th percentiles for continuous variables and percentages for categorical variables. Equality tests of patient characteristics were done using the Wilcoxon ranksum test. Parameter distribution plots and a Shapiro-Wilk test were used to check the pharmacokinetic parameters for departure from approximate normal distribution (results not shown). A Student's t test or Wilcoxon rank-sum test was then used as appropriate, depending on the p value of the Shapiro-Wilk test with a cut-off value of 0.05. Regression analysis was performed to identify significant explanatory covariates on prednisolone pharmacokinetics. All analyses were carried out using STATA 12.1.
Results
Participants
Fifty-nine patients were enrolled in the study. Two patients did not attend for blood sampling and one patient inadvertently took his morning medication prior to blood sampling. One patient was treated with azathioprine, and neither with tacrolimus nor with cyclosporine. Thus, data from 55 patients were eligible for analysis. Table 1 provides the baseline demographic and clinical characteristics of this cohort. Twenty-one (38 %) of the patients were treated with cyclosporine and 34 (62 %) were treated with tacrolimus. The groups were comparable with regard to age, body weight, glomerular filtration rate (GFR), haematocrit and albumin. Time post-transplantation trended towards being greater in the cyclosporine group explaining the slightly lower prednisolone dose in this group (a result of the common practice to slowly taper prednisolone dose over time). Total bilirubin was normal in both groups but slightly, and statistically significantly, greater in the cyclosporine group (Table 1) . Use of the known CYP3A4 and/or p-gp inhibitors diltiazem and/or lercanidipine was more frequent in the cyclosporine compared with the tacrolimus cohort (76 versus 44 %) ( Table 1) .
3.2 Dose-Adjusted Prednisolone Exposure Figure 1 shows total and free prednisolone concentrationtime profiles obtained in the 55 patients included in the final analysis. Prednisolone pharmacokinetic parameters in patients receiving cyclosporine versus tacrolimus are compared in Table 2 .
Primary Analysis
Based on LSS estimation, no significant difference in mean (SD 
Secondary Analysis
The elimination constant of free prednisolone k e was significantly lower in the cyclosporine group [0.164 h 
Discussion
This study is the first to compare the pharmacokinetics of prednisolone in adult male kidney transplant recipients on long-term cyclosporine versus tacrolimus therapy. No detectable impact of cyclosporine on total and free prednisolone exposure was observed, with the implication being that no adjustment in prednisolone dose is necessary when switching a transplant patient between calcineurin inhibitors. Five studies, with from 16 to 64 subjects, published between 1984 and 2004, compared prednisolone pharmacokinetics in patients treated with azathioprine or cyclosporine [8-10, 12, 14] . All studies found lower prednisolone clearance and/or increased prednisolone AUCs in the cyclosporine group. If it weren't for two contradicting studies published in 1987 and 1988 the interaction would have been firmly established. The study published in 1987 compared 25 kidney transplant recipients treated with cyclosporine with 25 patients on azathioprine [11] . No significant difference between the groups was detected for free (unbound) and total prednisolone metabolic clearance, renal clearance, volume of distribution and systemic availability. The authors questioned the validity of the previous studies, highlighting multiple b Sum of trapezes and extrapolating from 24 h to infinity using linear extension of last 3 observations and assuming C 0 = C 24 c Student's t test d Wilcoxon rank-sum test C n concentration at nth hour, d-tAUC x-y and d-fAUC x-y dose-adjusted area under the concentration-time curve from time x to y hours of total and free prednisolone, respectively, d-tC max and d-fC max dose-adjusted maximum observed plasma concentration of total and free prednisolone, respectively, tk e and fk e elimination rate constant derived using C 4 , C 6 and C 24 (=C 0 ) of total and free prednisolone, respectively methodological issues including unequal age and sex distribution, lack of information on the use of other potentially interacting medications, failure to account for prednisolone dose and insufficient duration of pharmacokinetic sampling and not measuring free prednisolone exposure. In 1988 one more study compared clearance of free prednisolone before and after kidney transplantation and also found no difference, albeit in a small population of six patients [13] . These methodological issues have all been addressed by our study. For the first time, we chose to study exclusively male patients.
There is evidence to support an impact of sex, and even hormonal cycle variation, on prednisolone exposure in fertile women [17, 18] . The most recent of the previously published cyclosporine-prednisolone interaction studies reported higher dose-adjusted prednisolone exposure (348 nmolÁh/L/ mg prednisolone) for 28 patients on cyclosporine compared with 15 patients on azathioprine (285 nmolÁh/L/mg prednisolone). However, prednisolone AUC was also found to be higher in females compared with males (415 versus 297 nmolÁh/L/mg prednisolone) [14] , with the highest AUCs seen in cyclosporine-treated women on oestrogen supplements (median 595 nmolÁh/L/mg prednisolone). This suggests that the unbalanced distribution of sex in this study (i.e. 15 women in the cyclosporine group (54 %) versus 5 (33 %) in the azathioprine group) might at least partially explain the observed difference in prednisolone exposure.
Antihypertensive therapy with lercanidipine or diltiazem was more common in the cyclosporine group (76 %) than in the tacrolimus group (44 %). This is because diltiazem is a popular cyclosporine adjuvant because of its dose (cost)-saving effect, owing to its inhibition of CYP3A4, in addition to controlling the blood pressure (hypertension is a common adverse effect of cyclosporine). In the analysis it is important to control for use of diltiazem and lercanidipine because the exerted inhibition of CYP3A4 and p-gp might affect the pharmacokinetics of prednisolone, which in this case might introduce bias in favour of rejecting the null hypothesis of cyclosporine not interacting with prednisolone pharmacokinetics. However, no effect of lercanidipine and/or diltiazem use on prednisolone pharmacokinetics was detected.
It is well established that it is the free fraction of drugs that are biologically active. Previous studies have therefore also been criticized for only measuring total prednisolone. Moreover, the choice of assay might be of importance. Specifically the use of immunoassays has been criticized for introducing a risk of misinterpretation caused by crossreactivity of prednisolone and cortisol [11, 19] . In the present study we estimated the pharmacokinetic parameters based on both free and total prednisolone concentrations determined exclusively using state-of-the-art ultra-highperformance liquid chromatography (UHPLC) with tandem mass spectrometric detection.
The previous studies discussed above all used azathioprine as a comparator for cyclosporine. Our study is the first to investigate the cyclosporine prednisolone interaction by using tacrolimus as a comparator. Despite tacrolimus being a CYP3A4 substrate, there is no indication in the literature suggesting significant p-gp/CYP3A4-inhibiting or -inductive properties [20, 21] . Theoretically, a study with a control group not using a calcineurin inhibitor would be ideal, but is not a protocol practiced by the Princess Alexandra Hospital transplant unit.
In a secondary analysis k e of free prednisolone was significantly lower in patients on cyclosporine compared with the tacrolimus. While this did not translate into a significant increase in free prednisolone exposure the finding is interesting because it suggests that cyclosporine may in fact influence elimination of prednisolone, albeit in a subtle and non-clinically relevant way. P-gp plays an excretory role for prednisolone not only in the liver, but also in the kidney (up to 25 % of prednisolone is excreted unchanged in the urine [22, 23] ), and cyclosporine is extensively bound to liver and kidney tissue [24] [25] [26] . One possible explanation for the observed results is that the concentration of cyclosporine in the intestinal mucosa is too low and/or too transient to inhibit the absorption of prednisolone to a degree that impacts on exposure, but is high and consistent enough in the liver and/or kidney to reduce the intrinsic free prednisolone clearance in these organs and thereby affects the slope of the terminal part of the elimination curve. However, it must be borne in mind that this study was not designed to specifically demonstrate a difference in elimination constants and that the k e estimates are based on limited data only.
Conclusion
This study did not detect a difference in total and free prednisolone exposure in adult male patients on cyclosporine or tacrolimus therapy. Hence, there is no need for prednisolone dose adjustment when substituting cyclosporine for tacrolimus (or vice versa) in adult male transplantation recipients.
